Retinal vein occlusion
Conditions
Interventions
RVO Patient Eye:None
Self-Control Healthy Eye:None
Healthy Control Group:None
Sponsors
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the RVO group: 1. Clinical diagnosis of unilateral RVO (BRVO or CRVO), accompanied by macular edema. 2. Age: 18 to 80 years old. 3. Received at least one intravitreal injection of anti-VEGF, and have complete baseline and post-treatment follow-up data. 4. High-quality OCT and OCTA examinations were conducted both at baseline (before treatment) and during follow-up. 5 The medical records are complete, including the results of BCVA, IOP, slit lamp and ophthalmoscopy examinations. Inclusion criteria for the control group (healthy eye group & healthy control group) : 1. Age and gender matched with those of the RVO group. 2. BCVA > 0.63. 3. IOP= 21mmHg. 4. The fundus examination was normal, with no eye diseases such as RVO, AMD, or DR. 5. High-quality OCT and OCTA images.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the RVO group: 1. Bilateral RVO. 2. Accompanied by other eye diseases that may affect macular structure or blood flow, such as diabetic retinopathy, age-related macular degeneration, pathological changes of high myopia, glaucoma (or IOP > 21 mmHg), uveitis, etc. 3. Refractive media opacity (such as severe cataracts and vitreous hemorrhage) leads to poor OCT/OCTA image quality. 4. Had received macular laser photocoagulation, vitreous surgery or hormone therapy before anti-VEGF treatment. 5. Incomplete follow-up data or loss to follow-up. Exclusion criteria for the control group (healthy eye group & healthy control group) : 1. Any known retinal or optic nerve diseases. 2. Have a history of ophthalmic surgery (except phacoemulsification for cataracts). 3. Refractive media opacity. 4. Systemic diseases (such as uncontrolled hypertension and diabetes) may affect the microcirculation of the retina.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Central Macular Thickness (CMT);Change in Vascular Density (VD) of Superficial (SCP) and Deep Capillary Plexuses (DCP) in the Macular Region;Change in Perfusion Capacity (PC) of Superficial (SCP) and Deep Capillary Plexuses (DCP) in the Macular Region;Change in Area of Foveal Avascular Zone (FAZ);Change in Perimeter of Foveal Avascular Zone (FAZ);Change in Morphological Irregularity of Foveal Avascular Zone (FAZ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Macular Edema Morphology (Intraretinal Fluid [IRF] / Subretinal Fluid [SRF]);Best Corrected Visual Acuity (BCVA);Intraocular Pressure (IOP);Correlation Analysis between OCT/OCTA Parameters and Improvement in BCVA and Reduction in CMT;Differences in CMT, VD, and FAZ Area between RVO Affected Eyes and Contralateral Healthy Eyes and Healthy Controls at Baseline;Vascular Density (VD) of Superficial (SCP) and Deep Capillary Plexuses (DCP) in the Macular Region;Perfusion Capacity (PC) of Superficial (SCP) and Deep Capillary Plexuses (DCP) in the Macular Region; | — |
Countries
China
Contacts
Public ContactLü Lin
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Outcome results
None listed